Fig. 6: Stability analysis and benchmark with other methods. | Nature Communications

Fig. 6: Stability analysis and benchmark with other methods.

From: The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

Fig. 6

a The ten most significant biomarkers across 25 models of five times repeated 5-fold cross-validation. b Boxplots of treatment effects in terms of hazard ratios for the predicted subgroups in the 25 test sets for the benchmarked methods, including standard treatment guidelines (std) and overall across all patients (null). The centre line depicts the median; the box represents the inter-quartile range (IQR) and the whiskers the interval 1.5 times the IQR. c Oncoprint showing identified subgroups for the benchmarked methods, including std, CMS subtypes, tumour sidedness and mutations in KRAS and NRAS. d Forest plot showing hazard ratios including 95% confidence intervals (CI) and amount of patients in the subgroup for which standard treatment is not recommended and which was found by subgroup analysis methods (new-std-negative). A Source Data file is provided, which contains the source data for the figure panels and the sample sizes of the conducted statistical tests.

Back to article page